Lifecore Biomedical Secures Major Tech Transfer Deal for 2028 Commercial Launch
Event summary
- Lifecore Biomedical signed a commercial site transfer agreement with a global pharmaceutical company for a marketed injectable drug product.
- The deal marks Lifecore's seventh late-stage commercial program and eleventh program added to its pipeline in 2026.
- The program is expected to generate commercial revenues starting in 2028.
- Lifecore's late-stage pipeline now contains thirteen programs with potential commercial revenues by the end of 2028.
The big picture
This agreement aligns with Lifecore's strategy to focus on high-impact, complex programs, positioning the company as a key player in the contract manufacturing of injectable pharmaceuticals. The deal underscores the growing demand for specialized CDMO capabilities in the biopharmaceutical industry, particularly for technically challenging products. With thirteen late-stage programs in its pipeline, Lifecore is poised to capitalize on the increasing outsourcing trends among global pharmaceutical companies.
What we're watching
- Pipeline Execution
- How Lifecore will manage the technical transfer and commercial production of this complex injectable drug product.
- Revenue Growth
- Whether the addition of this and other programs will sustain Lifecore's projected commercial revenues in 2028.
- Customer Diversification
- The pace at which Lifecore can expand its customer base with additional global pharmaceutical companies.